BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Cell-of-origin of prostate cancer and clinical heterogeneity - Dr 
 Esther Baena from CRUK Manchester Institute 
DTSTART:20181217T130000Z
DTEND:20181217T140000Z
UID:TALK114076@talks.cam.ac.uk
CONTACT:72001
DESCRIPTION:Personalized treatment for prostate cancer remains a challenge
  because there are no clear molecular subtypes to guide patient response. 
 Imaging\, PSA levels and pathological assessment of biopsies through the G
 leason grading system remain the gold standard for diagnosis and risk stra
 tification. Moreover\, most genomic campaigns analysed single biopsies wit
 h reduce analysis of their cellular landscape\, which limit the value of t
 his analysis in what is known to be a multifocal disease. By combining gen
 omic and multiparametric imaging analysis of high-risk prostate cancer pat
 ients\, we have characterized the radiogenomic landscape of multifocal pro
 state cancer (Parry\, Srivastana\, Ali et al\, EU Oncology\, Oct 2018). Mo
 reover\, coupling single-cell profiling and functional characterization by
  organoid-culture and in situ lineage-tracing analysis in mouse models\, w
 e have identified inherently castration-resistant cellular subpopulations 
 in the prostate defined by their unique cell-surface markers. In particula
 r\, our studies define LY6D as a marker for prostate progenitors and castr
 ation-resistant luminal cells\, which may serve as prognostic maker for ad
 vanced prostate cancer (Barros-Silva\, Linn\, Steiner\, in press). Further
  functional characterisation of the identified therapy-resistant prostate 
 luminal subpopulations will highlight their contribution to tumour subtype
 s thereby advancing patient stratification and setting a pipeline to devel
 op novel therapeutics.
LOCATION:CRUK CI Lecture Theatre (Room 001)
END:VEVENT
END:VCALENDAR